Delving into the Latest Updates on Shanxi Kangbao Biological Product Co. Ltd. with Synapse

Overview

Tags

Infectious Diseases

Hemic and Lymphatic Diseases

Other Diseases

Small molecule drug

Non-recombinant coagulation factor

Interferons

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	4
Hemic and Lymphatic Diseases	3
Immune System Diseases	2
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	3
Non-recombinant coagulation factor	3
Interferons	1
Prophylactic vaccine	1
Fusion protein	1

Top 5 Target	Count

gp41(Transmembrane glycoprotein gp41)	2
F10(Coagulation factor X)	1
factor IX(Coagulation factor IX)	1
Tubulin	1
Fibrinogen	1

主要目的：（1）评价康宝人纤维蛋白原在先天性纤维蛋白原减少或缺乏症患者中单次用药的药代动力学特征；（2）评价康宝人纤维蛋白原治疗先天性纤维蛋白原减少或缺乏症患者出血事件的有效性。次要目的：（1）评价康宝人纤维蛋白原治疗先天性纤维蛋白原减少或缺乏症患者出血事件的安全性；（2）评价已上市同类产品在先天性纤维蛋白原减少或缺乏症患者中单次用药的药代动力学特征。

[Translation]

Primary objectives: (1) To evaluate the pharmacokinetic characteristics of a single dose of Conbo human fibrinogen in patients with congenital fibrinogen deficiency or deficiency; (2) To evaluate the effectiveness of Conbo human fibrinogen in treating bleeding events in patients with congenital fibrinogen deficiency or deficiency. Secondary objectives: (1) To evaluate the safety of Conbo human fibrinogen in treating bleeding events in patients with congenital fibrinogen deficiency or deficiency; (2) To evaluate the pharmacokinetic characteristics of a single dose of similar products already on the market in patients with congenital fibrinogen deficiency or deficiency.

Start Date26 Dec 2024

Sponsor / Collaborator

Shanxi Kangbao Biological Product Co. Ltd.

NCT06560489

/ Enrolling by invitationPhase 1/2

Clinical Trial of Safety, Pharmacodynamics and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Primary Treatment of HIV-infected Patients

A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive HIV-Infected Individuals

Start Date02 Sep 2024

Sponsor / Collaborator

Shanxi Kangbao Biological Product Co. Ltd.

[+1]

CTR20243081

/ RecruitingPhase 2

在未接受过抗病毒治疗的HIV感染者中评估LP-98多次皮下注射的安全性、药效作用和药代动力学特征的随机、双盲、平行设计的探索性临床研究

[Translation] A randomized, double-blind, parallel-design exploratory clinical study to evaluate the safety, pharmacodynamics and pharmacokinetic characteristics of multiple subcutaneous injections of LP-98 in HIV-infected patients who have not received antiviral treatment

主要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的安全性和耐受性。次要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药效（PD）作用。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药代动力学（PK）特征。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的免疫原性。探索性目的：探索在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的病毒学治疗失败的情况。

[Translation]

Primary objective: To evaluate the safety and tolerability of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Secondary objectives: To evaluate the pharmacodynamic (PD) effect of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the pharmacokinetic (PK) characteristics of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the immunogenicity of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Exploratory objectives: To explore the failure of virological treatment after multiple subcutaneous injections of LP-98 in HIV-infected individuals who have not received antiviral treatment.

Start Date28 Aug 2024

Sponsor / Collaborator

Institute of Pathogen Biology Chinese Academy of Medical Sciences

[+1]

100 Clinical Results associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

28

Literatures (Medical) associated with Shanxi Kangbao Biological Product Co. Ltd.

Huagong Sheji Tongxun

Determination of tributyl phosphate in human Coagulation Factor VIII by pre-column derivation

Author: Gao, Hong-qin ; Wu, Peng-hui

Objective To establish a new method for the determining the contents of tri-Bu phosphate in the human coagulation factor VIII.Methods The content of tri-Bu phosphate was determined by gas chromatog.Results Under the selected experiment conditions, there was a good linear relationship for the content of tri-Bu phosphate in the range of 2-16μg/L.The RSD was 0.11% in the accuracy test.The RSD was 9.6% in the repeatability test.The average recovery rate was 91% with RSD 5.1%.Conclusion The method is accurate to determine the contents of tri-Bu phosphate in the human Coagulation Factor VIII, and can be used to determine the contents of tri-Bu phosphate in the human Coagulation Factor VIII.

Shanxi Yike Daxue Xuebao

Effect of sheep red blood cells and complement activity on anticomplementary activity in human intravenous immunoglobulin (PH4)

Author: Cui, Sumei ; Hao, Qinghua ; Gao, Hongqin

The effect of sheep red blood cells from different geog. origins and the titer of complement control on the anticomplementary activity in human i.v. Igs (PH4) (IVIG) was investigated.The CH50 method was used to determine the anticomplementary activity in human i.v. Igs.Anticomplementary activity in IVIG was determined with sheep red blood cells different geog. origins.Anticomplementary activity in IVIG was determined with different titers of complement controls.The sheep red blood cells from different titers of complement controls influenced the anticomplementary activity in IVIG.The sheep red blood cells from different geog. origins and complements with different titers may interfere the measurement of anticomplementary activity, thereby causing some deviations of the results.

Shanxi Yike Daxue Xuebao

Determination of antimony in human prothrombin complex by hydride generation-atomic absorption spectrometry

Author: Huo Jianfu ; Lian Jianke ; Wu Xieqian ; Han Yang ; Ren Fei

Objective To establish a method for the determination of antimony content in human prothrombin complex.Methods The content of antimony in human prothrombin complex was determined by hydride generation-at. absorption spectrometry.Results The calibration curve of antimony was linear in the range of 0-25.0 ng/mL with correlation coefficient higher than 0.99.The detection limit was 0.553 3 ng/mL and the quant. limit was 1.844 ng/mL.The recoveries were 95.93%-118.62%.Conclusion The method is simple,rapid,accurate and sensitive,and can be suitable for the determination of antimony in human prothrombin complex.

100 Deals associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shanxi Kangbao Biological Product Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

1

3

Phase 1

Phase 2

2

3

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Factor VIII(Shanxi Kangbao Biological Products) ( F10 )	Hemophilia A More	Approved
Human Prothrombin Complex Concentrate(Shanxi Kangbao Biological Products) ( factor IX )	Hemophilia B More	Approved
Human fibrinogen (Shanxi Kangbao Biological Product Co. Ltd.) ( Fibrinogen )	Afibrinogenemia More	Approved
Lipovirtide ( gp41 )	HIV Infections More	Phase 2
LP-98 ( gp41 )	HIV Infections More	Phase 2